From June 11 to 14, the 20th Annual Scientific Meeting of Asia Pacific Society of Cardiovascular and Interventional Radiology (APSCVIR 2026) grandly took place at Suzhou International Expo Center. The conference brought together top clinical specialists, research scholars and leading industrial enterprises from home and abroad to discuss cutting-edge advances and future trends in minimally invasive interventional diagnosis and treatment technologies.
During the APSCVIR 2026 Innovation Night, 15 authoritative specialists in interventional radiology from India gathered onsite. Kossel delivered a corporate presentation and showcased a full lineup of core products. The attending specialists spoke highly of the company’s comprehensive product portfolio, innovative R&D capabilities and platform-based operation model. This event served as an effective initiative for Kossel to precisely connect with overseas clinical practitioners and demonstrate the clinical value of its products.
As an enterprise deeply rooted in pan-vascular interventional therapy, Kossel exhibited its full product range at the grand event. Backed by consistent investment in technological R&D and a rigorous quality control system, a wide array of Kossel’s products have obtained MDR CE certification, granting complete market access qualifications for global markets.
The Asia Pacific region stands as a key priority in Kossel’s global expansion strategy. Throughout the exhibition, Kossel’s booth drew constant crowds. Our team received clinical physicians and distribution partners from multiple Asia-Pacific and Middle Eastern countries, including Saudi Arabia, India, Vietnam, Japan, South Korea, Malaysia, Pakistan and Singapore. During in-depth exchanges, both sides engaged in comprehensive, granular discussions covering clinical advantages of interventional devices, technological innovation and iteration, regional market promotion and in-depth strategic cooperation frameworks. These conversations enabled precise alignment with overseas market demands and thorough exploration of partnership opportunities, laying a solid foundation for the commercial rollout and widespread clinical adoption of Kossel’s products across the Asia Pacific, as well as follow-up customized R&D upgrades.
Kossel’s journey at APSCVIR 2026 has concluded successfully. Moving forward, Kossel will remain focused on product innovation and international development, expedite overseas certification of new products, and continuously enrich and refine its product portfolio. We will empower clinical diagnosis and treatment worldwide through high-quality vascular interventional medical devices and professional technical services.